Somatostatin receptor subtype 2 upregulation is very common in meningiomas, and the use of peptide receptor radionuclide therapy (PRRT) is recognized in recent European guidelines, with long-term stable disease and a long overall survival. Treatment efficacy of radionuclide treatments is correlated with tumour radiation absorbed dose. Meningioma patients with low tumour uptake might benefit less from treatment. Thus, a method to increase tumour uptake in these patients is needed. We describe a case treated with both intravenous and intra-arterial PRRT. Tumour uptake after intravenous PRRT was disappointing, and after intra-arterial administration significantly increased tumour uptake was seen. Patient had a partial response on imaging and r...
We present a partial response of peptide receptor radionuclide therapy (PRRT) with177Lu-DOTATATE in ...
International audienceObjective: Meningiomas express somatostatin receptor subtype 2 (SST2), which i...
Background: Meningiomas are the most common adult primary intracranial tumors in the United States. ...
Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-g...
BACKGROUND: The prognosis of patients with progressive meningioma after failure of surgery and radio...
none7noObjective: Few studies describe peptide receptor radionuclide therapy (PRRT) using (90)Y- or ...
International audienceSomatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (P...
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a prom...
Background: External beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma...
Purpose: There is no evidence-based systemic therapy for patients with progressive meningiomas for w...
Aim Here we describe the results of superselective intraarterial application of diagnostic Ga-68-DOT...
Currently, contrast-enhanced MRI is the method of choice for treatment planning and follow-up in pat...
Treatment-refractory meningiomas have a dismal prognosis and limited treatment options. Meningiomas ...
Because biopsy has a high risk of hemorrhage and the findings of CT and MRI are often ambiguous, esp...
We present a partial response of peptide receptor radionuclide therapy (PRRT) with177Lu-DOTATATE in ...
International audienceObjective: Meningiomas express somatostatin receptor subtype 2 (SST2), which i...
Background: Meningiomas are the most common adult primary intracranial tumors in the United States. ...
Purpose: Meningiomas are generally benign and in most cases surgery is curative. However, for high-g...
BACKGROUND: The prognosis of patients with progressive meningioma after failure of surgery and radio...
none7noObjective: Few studies describe peptide receptor radionuclide therapy (PRRT) using (90)Y- or ...
International audienceSomatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (P...
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a prom...
Background: External beam radiotherapy (EBRT) is the treatment of choice for irresectable meningioma...
Purpose: There is no evidence-based systemic therapy for patients with progressive meningiomas for w...
Aim Here we describe the results of superselective intraarterial application of diagnostic Ga-68-DOT...
Currently, contrast-enhanced MRI is the method of choice for treatment planning and follow-up in pat...
Treatment-refractory meningiomas have a dismal prognosis and limited treatment options. Meningiomas ...
Because biopsy has a high risk of hemorrhage and the findings of CT and MRI are often ambiguous, esp...
We present a partial response of peptide receptor radionuclide therapy (PRRT) with177Lu-DOTATATE in ...
International audienceObjective: Meningiomas express somatostatin receptor subtype 2 (SST2), which i...
Background: Meningiomas are the most common adult primary intracranial tumors in the United States. ...